Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated.</li><li>Costs were somewhat higher than we had forecast as was the cash burn.</li><li>A rights issue of SEK200m was announced, which will fund Pepaxti and the preclinical pipeline.</li></ul>

Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated.Costs were somewhat higher than we had forecast as was the cash burn.A rights issue of SEK200m was announced, which will fund Pepaxti and the preclinical pipeline.

Oncopeptides (Q4 initial take): Higher Costs and Rights Issue